Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

NYSE: BHVN · IEX Real-Time Price · USD
16.93
-0.26 (-1.51%)
At close: Sep 22, 2023, 4:00 PM
16.90
-0.03 (-0.18%)
After-hours: Sep 22, 2023, 7:40 PM EDT
-1.51%
Market Cap 1.16B
Revenue (ttm) n/a
Net Income (ttm) -430.80M
Shares Out 68.32M
EPS (ttm) -7.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 311,931
Open 17.14
Previous Close 17.19
Day's Range 16.69 - 17.18
52-Week Range 5.54 - 26.64
Beta n/a
Analysts Strong Buy
Price Target 24.80 (+46.49%)
Earnings Date Nov 8, 2023

About BHVN

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 928
Stock Exchange NYSE
Ticker Symbol BHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $24.8, which is an increase of 46.49% from the latest price.

Price Target
$24.8
(46.49% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy

- Taldefgrobep alfa is the only myostatin inhibitor in clinical development that targets both myostatin and activin A signaling, two key regulators of muscle mass and adipose tissue - RESILIENT, the p...

9 days ago - PRNewsWire

Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies

Examination of EEG in healthy subjects administered single doses of BHV-7000 confirmed central nervous system (CNS) activity consistent with effects observed with other antiseizure medications. EEG re...

18 days ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).

5 weeks ago - PRNewsWire

Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy

Taldefgrobep alfa, in Phase 3 global clinical development for Spinal Muscular Atrophy, granted EU Orphan Drug Designation in addition to previously receiving Fast Track and Orphan Drug Designation in ...

7 weeks ago - PRNewsWire

Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments

Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023 Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous...

7 weeks ago - PRNewsWire

Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates

NEW HAVEN, Conn. , July 27, 2023 /PRNewswire/ -- Biohaven Ltd.

2 months ago - PRNewsWire

Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day

Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team's fourth NDA in approximately 3 years Released additional data fr...

4 months ago - PRNewsWire

Biohaven to Present R&D Day at Yale School of Management

NEW HAVEN, Conn. , May 25, 2023 /PRNewswire/ -- Biohaven Ltd.

4 months ago - PRNewsWire

Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China) Appointed Nick Kozauer, M.D. a...

4 months ago - PRNewsWire

Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments

Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights; Phase 1 clinical trial initiation an...

6 months ago - PRNewsWire

Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse cla...

6 months ago - PRNewsWire

Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

BHV-7000 differs pharmacologically and structurally from other known Kv7 compounds in development BHV-7000 demonstrates potent anti-seizure activity without effects on neurobehavior in preclinical mod...

6 months ago - PRNewsWire

Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy

-  Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for Spinal Muscular Atrophy patients now granted Fast Track in addition to pr...

7 months ago - PRNewsWire

Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd.

9 months ago - PRNewsWire

Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

PALO ALTO, Calif.--(BUSINESS WIRE)--Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon ...

10 months ago - Business Wire

Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments

Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd.

11 months ago - PRNewsWire

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEW HAVEN, Conn. , Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd.

11 months ago - PRNewsWire

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including neuroscience, immunology and oncology Through its c...

11 months ago - PRNewsWire

Biohaven Announces Pricing of Public Offering of Common Shares

NEW HAVEN, Conn. , Oct. 20, 2022 /PRNewswire/ -- Biohaven Ltd.

1 year ago - PRNewsWire

Biohaven Announces Launch of Public Offering of Common Shares

NEW HAVEN, Conn. , Oct. 18, 2022 /PRNewswire/ -- Biohaven Ltd.

1 year ago - PRNewsWire

Biohaven CEO on on Pfizer's acquisition of the company

Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.

Other symbols: PFE
1 year ago - CNBC Television

Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients

Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders including epilepsy, pain and mood disorder...

1 year ago - PRNewsWire

Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)

NEW HAVEN, Conn. , Sept. 29, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 year ago - PRNewsWire

Biohaven Announces Record Date for Anticipated Spin-Off

NEW HAVEN, Conn. , Sept. 18, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 year ago - PRNewsWire